IRD

Opus Genetics Inc

3.69

Nov 02 • 1:32 PM ET +0.02 (0.54%)

Healthcare Biotechnology USA Small NASD

Oct 29, 7:06 AMOpus Genetics appoints Andrew Murphy, Ph.D., as chief scientific officer to strengthen scientific leadership

Peers: MGTX FDMT LENZ EYPT OCUL OCS KOD BLTE ALDX KALA

| Held by: VTI IWM VXF IWO VTWO VFMO IWC SURI VTWG GSSC

Scroll to Statements

Index	RUT
Market Cap	306.99M
Enterprise Value	254.38M
Income	-107.61M
Sales	9.86M
Book/sh	-0.16
Cash/sh	1.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	28
IPO	Nov 30, 2004

P/E	-
Forward P/E	-
PEG	-
P/S	31.14
P/B	-
P/C	3.46
P/FCF	-
EV/EBITDA	-
EV/Sales	25.80
Quick Ratio	12.19
Current Ratio	12.19
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.38
EPS next Y	-0.70
EPS next Q	-0.15
EPS this Y	-28.82%
EPS next Y	31.68%
EPS next 5Y	33.47%
EPS past 3/5Y	- 31.49%
Sales past 3/5Y	-29.11% -
EPS Y/Y TTM	24.84%
Sales Y/Y TTM	-36.09%
EPS Q/Q	-18.70%
Sales Q/Q	-73.80%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	10.66% -71.27%

Insider Own	18.89%
Insider Trans	-13.13%
Inst Own	67.45%
Inst Trans	16.50%
ROA	-163.50%
ROE	-4796.52%
ROIC	-463.48%
Gross Margin	99.46%
Oper. Margin	-513.47%
Profit Margin	-1091.82%
SMA20	-7.14%
SMA50	-17.31%
SMA200	-11.95%
Trades

Shs Outstand	82.65M
Shs Float	67.48M
Short Float	19.77%
Short Ratio	5.36
Short Interest	13.34M
52W High	7.07 -47.81%
52W Low	1.70 117.06%
Volatility	7.70% 7.84%
ATR (14)	0.32
RSI (14)	40.28
Beta	0.81
Rel Volume	0.30
Avg Volume	2.49M
Volume	469,255

Perf Week	11.14%
Perf Month	-19.43%
Perf Quarter	-0.54%
Perf Half Y	-29.31%
Perf YTD	83.58%
Perf Year	60.43%
Perf 3Y	34.18%
Perf 5Y	-13.58%
Perf 10Y	-94.59%
Recom	1.00
Target Price	13.47
Prev Close	3.67
Price	3.69
Change %	0.54%

Consensus

Strong Buy

Avg. Price Target

$13.47

Implied Upside

+265.0%

Analysts14incl. previous ratings

Rating Distribution13 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 29, 2026	Initiated	TTD Cowen	Buy
Jun 23, 2026	Initiated	RRBC Capital Mkts	Outperform	$10	+171.0%
Jun 04, 2026	Initiated	GGuggenheim	Buy	$16	+333.6%
May 21, 2026	Initiated	LLeerink Partners	Outperform	$10	+171.0%
Apr 28, 2026	Initiated	CCitizens	Mkt Perform	$12	+225.2%
Mar 30, 2026	Initiated	CCantor Fitzgerald	Overweight	$15	+306.5%
Mar 16, 2026	Initiated	OOppenheimer	Outperform	$10	+171.0%
Jan 20, 2026	Initiated	BBTIG Research	Buy	$7	+89.7%
Dec 10, 2025	Initiated	RB. Riley Securities	Buy	$9	+143.9%
Nov 25, 2025	Initiated	PPiper Sandler	Overweight	$7	+89.7%
Oct 29, 2025	Initiated	WWedbush	Outperform	$8	+116.8%
Oct 16, 2025	Initiated	CChardan Capital Markets	Buy	$9	+143.9%
Apr 11, 2025	Initiated	CCraig Hallum	Buy	$6	+62.6%
Nov 13, 2024	Resumed	HH.C. Wainwright	Buy	$8	+116.8%

Oct-29-26 07:00AM	Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations (GlobeNewswire)
Oct-21-26 07:00AM	Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness (GlobeNewswire)
Oct-19-26 06:44AM	FDA approves Viatris' Ryzumvi for adult presbyopia (Pharmaceutical Business Review)
Oct-16-26 01:58PM	Opus Genetics Secures FDA Approval For Eye Drops Set To Receive Milestone Payment (Stocktwits) -5.19%
12:00PM	Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire)
04:00PM	Loading…
Oct-15-26 04:00PM	Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 (GlobeNewswire)
Oct-13-26 07:00AM	Opus Genetics to Present at the Chardan Annual Healthcare Conference (GlobeNewswire) -8.62%
Oct-05-26 07:21AM	FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application (Stocktwits)
Sep-09-26 01:19PM	IRD Stock Hits Over 5-Year Highs Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial (Stocktwits) +32.03%
10:37AM	Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027 (InvestorsHub)
07:00AM	Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 (GlobeNewswire)
Sep-02-26 07:00AM	Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences (GlobeNewswire) +16.19%
Sep-01-26 08:59AM	Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data (InvestorsHub) +5.80%
Aug-19-26 04:01PM	Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.30%
Aug-06-26 07:00AM	Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update (GlobeNewswire)
07:00AM	Loading…
Aug-03-26 07:00AM	Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease (GlobeNewswire)
Jul-09-26 07:00AM	Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results (GlobeNewswire)
Jul-06-26 07:00AM	Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease (GlobeNewswire)
Jun-26-26 09:15AM	Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes (GlobeNewswire) +7.53%
Jun-16-26 04:05PM	Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases (GlobeNewswire)
Jun-02-26 07:00AM	Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts (GlobeNewswire)
May-28-26 04:01PM	Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 08:00AM	Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-26 07:00AM	Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference (GlobeNewswire)
May-12-26 07:00AM	Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update (GlobeNewswire)
May-07-26 04:30PM	Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases (GlobeNewswire) -6.90%
07:00AM	Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study (GlobeNewswire)
May-04-26 04:30PM	Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program (GlobeNewswire)
Apr-27-26 08:00AM	Opus Genetics to Participate in Leading Medical Conferences in May 2026 (GlobeNewswire)
Apr-10-26 06:59AM	Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Apr-06-26 07:00AM	Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital (GlobeNewswire)
Mar-24-26 07:00AM	Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 (GlobeNewswire)
Mar-10-26 08:30AM	Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update (GlobeNewswire)
Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +7.53%
Mar-03-26 08:00AM	Opus Genetics to Present at Upcoming Investor Conferences in March 2026 (GlobeNewswire)
Feb-27-26 10:10AM	Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting (GlobeNewswire) +15.88%
Feb-25-26 06:59AM	Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire)
Feb-13-26 07:30AM	Opus Genetics Announces $25 Million Private Placement (GlobeNewswire) +7.37%
Feb-02-26 08:00AM	Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 (GlobeNewswire)
Jan-27-26 07:00AM	Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa (GlobeNewswire)
Jan-09-26 07:20AM	Opus Genetics highlights 2025 progress, upcoming 2026 catalysts (TipRanks)
Jan-08-26 07:00AM	Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts (GlobeNewswire) -5.21%
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-16-25 04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.61%
Dec-11-25 07:00AM	Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-09-25 07:00AM	Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease (GlobeNewswire)
Dec-02-25 04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Nov-29-25 01:26AM	Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With "Overweight" Rating and $7 PT (Insider Monkey)
Nov-20-25 08:00AM	Opus Genetics to Participate in Upcoming Investment Conferences (GlobeNewswire)
Nov-13-25 07:00AM	Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease (GlobeNewswire)
Nov-12-25 08:30AM	Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Nov-06-25 05:35PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease (GlobeNewswire)
07:00AM	Opus Genetics Announces $23 Million Registered Direct Offering (GlobeNewswire)
Nov-05-25 10:00AM	Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:40AM	Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates (Zacks)
Nov-04-25 05:15PM	Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 08:00AM	Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness (GlobeNewswire) -6.96%
Oct-14-25 08:00AM	Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Oct-02-25 08:00AM	Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 (GlobeNewswire)
Oct-01-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice (Zacks) +9.09%
Sep-30-25 07:00AM	Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) (GlobeNewswire) -7.82%
Sep-16-25 03:42AM	Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics (Zacks)
Sep-15-25 03:00PM	The Under $20 Breakout Trio Investors Shouldn't Ignore (Zacks)
Sep-12-25 08:00AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-25 08:00AM	Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire)
Sep-03-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-02-25 08:00AM	Opus Genetics Appoints Rob Gagnon as Chief Financial Officer (GlobeNewswire)
Aug-27-25 08:00AM	Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September (GlobeNewswire)
Aug-18-25 08:00AM	Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 (GlobeNewswire)
Aug-13-25 05:40PM	Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.27%
04:30PM	Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Aug-07-25 08:25AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Jul-23-25 08:00AM	Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness (GlobeNewswire)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-03-25 04:30PM	Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-25 06:55AM	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire) +5.13%
Jun-23-25 08:00AM	Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program (GlobeNewswire)
Jun-02-25 08:00AM	Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire) +9.60%
May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update (GlobeNewswire)
May-14-25 06:55PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 08:00AM	Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May (GlobeNewswire)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 08:00AM	Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate (GlobeNewswire)
May-05-25 08:00AM	Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
Apr-15-25 10:36AM	PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath (GlobeNewswire)
Apr-11-25 03:47PM	Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns (GlobeNewswire)
Apr-08-25 08:00AM	Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases (GlobeNewswire) -11.50%
Apr-07-25 08:00AM	Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress (GlobeNewswire)
Apr-02-25 08:00AM	Opus Genetics to Participate in Upcoming Investor Conference in April (GlobeNewswire)
Mar-31-25 08:20AM	Opus Genetics Announces Financial Results for Full Year 2024 (GlobeNewswire)
Mar-21-25 05:03PM	Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics (GlobeNewswire) +9.57% -8.73%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHACHLE JOSEPH K	Chief Operating Officer	Oct 23 '26	Sale	3.56	4,767	16,994	286,673	Oct 27 04:47 PM
YERXA BENJAMIN R	President	Oct 23 '26	Sale	3.54	33,189	117,365	670,917	Oct 27 04:41 PM
Gagnon Robert E.	Chief Financial Officer	Oct 23 '26	Sale	3.55	14,000	49,650	542,375	Oct 27 04:29 PM
Magrath George	Chief Executive Officer	Oct 23 '26	Sale	3.58	9,591	34,384	2,038,894	Oct 27 04:20 PM
YERXA BENJAMIN R	Officer	Oct 23 '26	Proposed Sale	3.54	33,189	117,365		Oct 23 04:57 PM
Gagnon Robert E.	Officer	Oct 23 '26	Proposed Sale	4.01	14,000	56,140		Oct 23 04:04 PM
Magrath George	Officer	Oct 23 '26	Proposed Sale	3.59	9,591	34,384		Oct 23 02:48 PM
Foundation Fighting Blindness	Director	Sep 30 '26	Sale	4.96	556,000	2,755,981	3,236,171	Oct 02 07:47 PM
Magrath George	Chief Executive Officer	Sep 09 '26	Option Exercise	1.15	392,157	450,981	2,124,026	Sep 11 04:09 PM
Gallagher Cam	Director	Sep 08 '26	Option Exercise	1.15	784,314	901,961	2,800,111	Sep 08 04:05 PM
Gagnon Robert E.	Chief Financial Officer	Sep 03 '26	Sale	4.54	28,000	127,212	556,375	Sep 08 04:05 PM
Gagnon Robert E.	Officer	Sep 03 '26	Proposed Sale	4.45	28,000	124,600		Sep 03 04:11 PM
YERXA BENJAMIN R	President	Jul 23 '26	Sale	2.97	7,429	22,064	704,106	Jul 27 04:08 PM
SCHACHLE JOSEPH K	Chief Operating Officer	Jul 23 '26	Sale	2.94	4,644	13,653	291,440	Jul 27 04:07 PM
Magrath George	Chief Executive Officer	Jul 23 '26	Sale	2.95	9,475	27,926	1,731,869	Jul 27 04:07 PM
Gagnon Robert E.	Chief Financial Officer	Jul 23 '26	Sale	2.95	7,783	22,942	584,375	Jul 27 04:06 PM
Gagnon Robert E.	Officer	Jul 23 '26	Proposed Sale	3.05	7,783	23,738		Jul 23 05:21 PM
Magrath George	Officer	Jul 23 '26	Proposed Sale	3.05	9,475	28,899		Jul 23 05:17 PM
SCHACHLE JOSEPH K	Officer	Jul 23 '26	Proposed Sale	2.94	4,644	13,653		Jul 23 01:09 PM
YERXA BENJAMIN R	Officer	Jul 23 '26	Proposed Sale	2.97	7,429	22,064		Jul 23 12:46 PM
Foundation Fighting Blindness	Director	May 18 '26	Sale	4.35	1,700,000	7,395,000	3,792,171	May 20 07:29 PM
YERXA BENJAMIN R	President	Apr 23 '26	Sale	5.24	7,470	39,121	711,535	Apr 27 04:28 PM
SCHACHLE JOSEPH K	Chief Operating Officer	Apr 23 '26	Sale	5.22	4,697	24,519	296,084	Apr 27 04:28 PM
Zaremba Rabourn Amy	Head of Fin. Quality Assurance	Apr 23 '26	Sale	5.20	1,641	8,540	188,671	Apr 27 04:27 PM
Magrath George	Chief Executive Officer	Apr 23 '26	Sale	5.22	9,511	49,647	1,741,344	Apr 27 04:27 PM
Jayagopal Ashwath	Chief Scientific & Dev. Ofc.	Apr 23 '26	Sale	5.19	7,542	39,156	509,233	Apr 27 04:26 PM
Gagnon Robert E.	Chief Financial Officer	Apr 23 '26	Sale	5.18	7,842	40,658	592,158	Apr 27 04:26 PM
SCHACHLE JOSEPH K	Officer	Apr 23 '26	Proposed Sale	5.22	4,697	24,519		Apr 23 06:11 PM
YERXA BENJAMIN R	Officer	Apr 23 '26	Proposed Sale	5.24	7,470	39,121		Apr 23 05:55 PM
Magrath George	Officer	Apr 23 '26	Proposed Sale	13.39	9,511	127,327		Apr 23 04:36 PM
Gagnon Robert E.	Officer	Apr 23 '26	Proposed Sale	5.18	7,842	40,658		Apr 23 04:08 PM
Jayagopal Ashwath	Officer	Apr 23 '26	Proposed Sale	5.19	7,542	39,156		Apr 23 03:49 PM
SCHACHLE JOSEPH K	Chief Operating Officer	Mar 16 '26	Sale	5.25	3,719	19,525	300,781	Mar 18 04:12 PM
Zaremba Rabourn Amy	Head of Fin. Quality Assurance	Mar 16 '26	Sale	5.25	2,816	14,770	190,312	Mar 18 04:11 PM
Magrath George	Chief Executive Officer	Mar 16 '26	Sale	5.21	24,438	127,327	1,750,855	Mar 18 04:10 PM
Jayagopal Ashwath	Chief Scientific & Dev. Ofc.	Mar 16 '26	Sale	5.12	3,719	19,046	516,775	Mar 18 04:09 PM
Magrath George	Officer	Mar 16 '26	Proposed Sale	5.21	24,438	127,327		Mar 16 04:54 PM
Gallagher Cam	Director	Dec 29 '25	Buy	1.97	83,000	163,419	83,000	Dec 31 04:33 PM
Gallagher Cam	Director	Dec 29 '25	Buy	1.98	81,000	160,275	1,891,430	Dec 31 04:33 PM
Foundation Fighting Blindness	Director	Dec 09 '25	Sale	2.15	4,000,000	8,600,000	5,492,171	Dec 11 05:35 PM

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

M.D.Dr. George Magrath M.B.A.

President & DirectorDr. Benjamin R. Yerxa Ph.D.

Chief Operating OfficerMr. Joseph K. Schachle MBA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IRD

Opus Genetics Inc

Upgrade your Finviz experience